CareDx(CDNA)

Search documents
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
Zacks Investment Research· 2024-02-26 15:21
Wall Street analysts forecast that CareDx (CDNA) will report quarterly loss of $0.24 per share in its upcoming release, pointing to a year-over-year decline of 242.9%. It is anticipated that revenues will amount to $65.1 million, exhibiting a decline of 21% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company ...
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
Businesswire· 2024-02-21 12:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings, Transplantati ...
CareDx Issues Statement in Patent Infringement Case
Businesswire· 2024-01-27 02:45
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 (the ‘180 patent) and found to have infringed on Natera patent 11,111,544 (the ‘544 patent). ...
CareDx(CDNA) - 2023 Q3 - Earnings Call Transcript
2023-11-09 01:13
CareDx, Inc (NASDAQ:CDNA) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and Testing Services Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Michael Goldberg - Chairperson of the Board Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Jacob Krahenbuhl - Stephens Dipesh Patel - H.C. Weinright Operator Goo ...
CareDx(CDNA) - 2023 Q3 - Quarterly Report
2023-11-07 16:00
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regu ...
CareDx(CDNA) - 2023 Q2 - Earnings Call Transcript
2023-08-09 02:38
CareDx, Inc. (NASDAQ:CDNA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Reg Seeto - President, CEO Abhishek Jain - CFO Robert Woodward - SVP, R&D Conference Call Participants Andrew Cooper - Raymond James Brandon Couillard - Jefferies Alex Nowak - Craig-Hallum Capital Mason Carrico - Stephens Inc. Operator Greetings, and welcome to the CareDx, Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a remind ...
CareDx(CDNA) - 2023 Q2 - Quarterly Report
2023-08-07 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36536 __ ...
CareDx(CDNA) - 2023 Q1 - Earnings Call Transcript
2023-05-12 19:39
CareDx, Inc. (NASDAQ:CDNA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Reg Seeto - President, CEO Abhishek Jain - CFO Robert Woodward - SVP, R&D Conference Call Participants Matt Sykes - Goldman Sachs Andrew Cooper - Raymond James Brandon Couillard - Jefferies Mark Massaro - BTIG Alex Nowak - Craig-Hallum Capital Group Mason Carrico - Stephens Inc. Operator Greetings. And welcome to the CareDx, Inc. First Quarter 2023 Earnings Con ...
CareDx(CDNA) - 2023 Q1 - Quarterly Report
2023-05-09 16:00
Table of Contents For the transition period from to Commission file number: 001-36536 __________________________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check m ...
CareDx(CDNA) - 2022 Q4 - Earnings Call Transcript
2023-02-28 03:37
CareDx, Inc. (NASDAQ:CDNA) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Matthew Sykes - Goldman Sachs Mason Carrico - Stephens Alex Nowak - Craig-Hallum Capital Group Mark Massaro - BTIG Yi Chen - H.C. Wainright Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Fourth Quarter 2022 Earnings Conference Call. Today’s ...